Drug Database
IP

IPDAS (IPDAS)

✓ Approved

Elan · therapeutic agent

What is IPDAS?

IPDAS is a therapeutic agent developed by Elan. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesIPDAS
CompanyElan
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Elan

Therapeutic Indications

IPDAS is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedAsia-Pacific journal of oncology nursing2026-09-27

Development and pilot testing of a web-based decision aid for fertility-preservation decisions among women with cancer in South Korea.

Han Jeehee J, Jang Mina M, Kim Seul Ki SK, Park Jinyoung J

Fertility preservation is an important concern for women of reproductive age with cancer. Many receive insufficient counseling and may experience decisional conflict and psychological distress. This study aimed to develop and pilot test SHARE, a web-based decision aid supporting fertility-preservation decisions among women of reproductive age with cancer in South Korea, using a process informed by the Ottawa Decision Support Framework and the International Patient Decision Aid Standards (IPDAS). This development and pilot-testing study included scoping, steering-group formation, a needs assessment with 16 women who had completed cancer treatment and 7 health care professionals, evidence synthesis, iterative prototyping, think-aloud alpha testing (n = 4), and beta testing with post-treatment participants (n = 15) assessing acceptability, user experience, and the importance assigned to decision factors. SHARE comprises seven interactive modules covering fertility risks, fertility-preservation options, values clarification, and preparation for clinical discussions. Alpha testing identified navigation, terminology, personalization, and visual-design issues. In beta testing, mean module information-presentation ratings ranged from 2.73 to 3.40 on a 4-point scale; 11 of 15 participants (73.3%) reported that SHARE was useful for decision-making, and 12 of 15 (80.0%) perceived the information as balanced. User Experience Questionnaire scores were positive for Perspicuity (1.42), Efficiency (0.98), and Dependability (0.97) and neutral for Attractiveness (0.64), Stimulation (0.33), and Novelty (-0.02). The importance of starting cancer treatment as soon as possible was rated 9.67/10, compared with 6.33/10 for having a child in the future. This small post-treatment pilot provided preliminary evidence of acceptability and stronger pragmatic than hedonic user-experience ratings; it did not establish decisional or clinical effectiveness. Prospective evaluation in newly diagnosed women across cancer types is warranted.

PMID 42799054
Read full article →
PubMedHealth expectations : an international journal of public participation in health care and health policy2026-09-25

Digital Patient Decision Aids for Endometriosis Management: A Scoping Review.

Pittet Océane O, Delvallée Marion M, Pluchino Nicola N, Selby Kevin K et al.

Endometriosis treatment requires women to navigate complex, preference-sensitive decisions. Patient Decision Aids (PtDAs) help patients make value-aligned choices. However, the scope and quality of digital PtDAs for endometriosis, and the cap acity of conversational AI platforms to act as PtDAs, remain unclear. Systematically map digital PtDAs for women of reproductive age with endometriosis, describe their content, development, and evaluation, and assess quality and replicability. Electronic databases, Google Scholar, grey literature, and web searches were conducted from inception to July 2025. We included digital PtDAs for women aged 18-49 with a clinical diagnosis of endometriosis that met the minimum criteria established to qualify as a PtDA. Additionally, we developed a prompt to generate five PtDAs using conversational AI platforms, mirroring patient or clinician decision-support queries. Two independent reviewers extracted data per Joanna Briggs Institute (JBI) scoping reviews methodology. IPDAS criteria (requirements for PtDAs) and TIDieR items (intervention reporting) were applied; data were summarised descriptively and qualitatively. Ten PtDAs were included (five expert-developed; five AI-generated). Overall, most addressed pharmacological and surgical options, while AI-generated PtDAs included more complementary therapies. All described the health condition, decision, and options with balanced pros/cons, but most failed on important IPDAS criteria for high-quality PtDAs. Most expert-developed PtDAs also lacked transparent development reporting and had not been formally evaluated. Few digital PtDAs for endometriosis were identified; most showed limited adherence to IPDAS criteria, poor reporting transparency, and absent formal evaluation.

PMID 42788763
Read full article →
PubMedSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026-09-11

IDECIDE breast surgery patient decision aid: Development and testing of a quality of life-integrated decision support tool.

Adams Monica M, Durden Jakob A JA, Leslie Sarah E SE, Vemuru Sudheer R SR et al.

Surgery is the primary treatment for early-stage breast cancer, with breast-conserving surgery and mastectomy offering similar survival outcomes. Shared decision-making (SDM) and patient decision aids (PDAs) can help patients weigh options, but many PDAs lack long-term quality of life (QoL) data. The IDECIDE Breast Surgery PDA addresses this gap by embedding real-world, institution-specific patient-reported QoL data directly into the PDA, allowing patients to consider survivorship outcomes while actively deliberating between surgical options rather than evaluating QoL only after a decision has been made. Developed using the Ottawa Decision Support Framework and International Patient Decision Aids Standards (IPDAS), the PDA underwent iterative testing for understandability, actionability, and acceptability. Nine patients and six clinicians assessed the PDA via surveys and semi-structured interviews. Thematic rapid coding analysis was applied to interview transcripts. Patients rated the PDA's understandability at 98.7% and actionability at 92.0%, with 100% finding the length and amount of information appropriate. Clinicians rated understandability at 100% and actionability at 95.2%. Both groups found the PDA balanced in presenting treatment options, with clinicians scoring 42.5/46.0 on IPDAS criteria. Patient interviews highlighted clarity, visual aids, and inclusion of QoL data, with suggestions for additional content and improved formatting. Clinicians recommended addressing contralateral breast surgery and endocrine therapy concerns. The IDECIDE PDA effectively integrates QoL data and supports SDM, with high ratings from both patients and clinicians. Future work will implement suggested revisions and pilot the PDA with newly diagnosed breast cancer patients.

PMID 42722882
Read full article →
PubMedHealth science reports2026-08-27

Stroke Reduction Therapies, Shared Decision-Making, and Patient Decision Aids: An Opportunity for Improved Quality and Inclusion in the Management of Atrial Fibrillation-A Perspective Piece.

Jackson Larry R LR, Matlock Daniel D, Thomas Kevin L KL

Atrial fibrillation (AF) is associated with 20% of the ischemic strokes in the United States. Atrial fibrillation related ischemic strokes can be reduced by pharmacologic and non-pharmacologic therapies. The decision-making process for selecting stroke reduction therapies is complex and should be individualized based on patient preferences and values, the risk and benefits of treatment, and the impact on the quality of life. Shared decision-making (SDM) operationalized through patient decision aids (PDAs) provides an opportunity to improve the decision-making process for stroke reduction therapies used in AF. Unfortunately, a limited number of PDAs for stroke reduction therapies in AF exist. Furthermore, it is unclear whether these aids were created in an evidence-based fashion and tailored to specific populations. This perspective advocates for future amendments to the International Patient Decision Aids Standards (IPDAS) and the National Standards for the Certification of Patient Decision Aids that will facilitate the creation of evidenced based PDAs that move beyond a one-size fits all approach. Specifically, creation of diverse stakeholder advisory teams that utilize usability testing to create decision aids that are culturally responsive and perhaps tailored to vulnerable populations. Racial and ethnic minoritized populations with AF have the highest burden of poor outcomes. Black patients with AF had a twofold higher rate of stroke versus White patients (27.2 vs. 12.8 per 1000 per years) in the Atherosclerosis Risk in Communities Study. We hypothesize that SDM operationalized through PDAs has the chance to potentially reduce racial and ethnic disparities in the utilization of different stroke reduction therapies for AF. The process of SDM conducted via PDAs can improve the decision-making process for stroke reduction therapies in AF. Future studies should assess the feasibility of creating culturally tailored decision aids as well as their effectiveness in increasing the uptake of stroke reduction therapies.

PMID 42657155
Read full article →
PubMedCJC open2026-07-22

Appraising the Quality of Patient Decision Aids for Brain and Heart Health: An Environmental Scan with a Health Equity Lens.

Lewis Krystina B KB, Goge Sandhya S, Kiss Alda A, Carley Meg M et al.

New brain-heart clinical practice guidelines recommend provision of patient decision aids (PtDAs) to support people with or at risk of brain and heart conditions. We aimed to identify and appraise the quality of PtDAs addressing brain-heart conditions and their consideration of health equity. We conducted an online environmental scan to identify publicly available PtDAs. Two reviewers independently searched, extracted data, and appraised their quality using International Patient Decision Aid Standards (IPDAS) criteria, the Patient Education Materials Assessment Tool (PEMAT), and the PROGRESS-Plus framework for health equity. Of 2549 resources identified, 51 PtDAs were eligible. Nine addressed a combined brain-heart decision, 36 addressed primarily cardiovascular conditions with brain implications, and 6 addressed primarily brain conditions with heart implications. Few focused on brain-heart conditions concomitantly. None addressed dementia, and only one addressed depression as a primary condition with cardiovascular risk addressed as a secondary consideration. The mean IPDAS essential criteria score was 5.8 of 7 (SD 1.5, range 1-7). For PEMAT-P (for printable materials), 91% PtDAs achieved an adequate understandability rating (≥ 70%), and 56% achieved an adequate actionability rating (≥ 70%). The most frequently reported PROGRESS-Plus healthy equity items were age (80%), gender/sex (45%), and socioeconomic status (39%). Brain-heart guidelines recommend PtDA use, but our environmental scan highlighted the need for more of these important interventions. Few PtDAs focused on brain and heart conditions concomitantly, none addressed dementia, and only one addressed depression, which frequently coexist with cardiac conditions. PtDAs also lacked actionable guidance within an equity-informed framework to support quality decisions and decision-making processes for all.

PMID 42483023
Read full article →
PubMedBMC medical informatics and decision making2026-07-12

A systematic review of patient decision aids for hypertension.

Berghold Jan J, Fischer Lena L, Pachanov Alexander A, Schewe Leon Vincent LV et al.

Hypertension is a major cause of premature death and a modifiable risk factor for cardiovascular disease. Effective management includes both pharmacological treatment strategies, including antihypertensive medications, and non-pharmacological treatment strategies, such as lifestyle changes. Shared decision making (SDM) between patients and healthcare professionals is essential to determine the most appropriate treatment for hypertension. Patient decision aids (PDAs) facilitate SDM by providing information on treatment options and helping patients to clarify their values and preferences. However, there is no comprehensive comparison of PDAs for hypertension. This systematic review aimed to identify and evaluate PDAs for arterial hypertension using the International Patient Decision Aid Standards (IPDAS) criteria. A comprehensive search of bibliographic databases (PubMed, Embase) and gray literature (Google Scholar, Google) was performed in October 2023 and updated in April 2026. Studies and tools were included if they presented a PDA for patients with arterial hypertension, met the IPDAS definition of a PDA and were in German or English. Two researchers screened the literature, extracted data and assessed the quality of the PDAs using the IPDAS Minimal Criteria. Data were synthesized narratively. Of 1,874 records screened, five PDAs met the inclusion criteria. These PDAs were developed between 2019 and 2024 and originated from the United States, United Kingdom, and Germany. All PDAs addressed the two option areas of medication and lifestyle but differed in the number of individual treatment options presented (range: 2-12 options) and the level of detail in which the options were addressed. All five PDAs were accessible online. Common design features of the PDAs included an option grid format for presenting treatment options with associated benefits and adverse effects, visuals and graphics to enhance comprehension, and value clarification. Quality assessments showed varying levels of compliance with the IPDAS criteria, with overall scores ranging from 49/116 to 87/116. Few PDAs exist despite the prevalence of hypertension. PDAs varied in quality and format, highlighting gaps in the development process. Further research is needed to evaluate the effectiveness of PDAs for hypertension and to determine which formats are most effective in supporting SDM in different patient populations. Not applicable.

PMID 42436484
Read full article →

+167 more articles available with a free account

Sign up free to view all articles →

Ask about IPDAS